Hepion Pharmaceuticals, Inc., a biopharmaceutical firm, is making significant strides towards developing drug therapy for chronic liver ailments in the United States. Its focus is centered on bringing Rencofilstat, a cyclophilin inhibitor, to market. Following the completion of Phase 2a clinical trials, Rencofilstat targets multiple pathologic pathways related to liver disease progression, and is currently in clinical-phase development to address non-alcoholic steatohepatitis (NASH). Nonclinical studies on reducing liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH have also been conducted by Hepion Pharmaceuticals, Inc. The firm's product range has demonstrated antiviral activities against hepatitis B, C, and D viruses by employing several mechanisms. Hepion Pharmaceuticals, Inc. was formerly known as ContraVir Pharmaceuticals, Inc., and the company renamed itself in July 2019. Hepion Pharmaceuticals, Inc. was established in 2013 and hosts its headquarters in Edison, New Jersey.
Hepion Pharmaceuticals, Inc.'s ticker is HEPA
The company's shares trade on the NASDAQ stock exchange
They are based in Edison, New Jersey
There are 11-50 employees working at Hepion Pharmaceuticals, Inc.
It is https://hepionpharma.com/
Hepion Pharmaceuticals, Inc. is in the Healthcare sector
Hepion Pharmaceuticals, Inc. is in the Biotechnology industry
The following five companies are Hepion Pharmaceuticals, Inc.'s industry peers: